Rapid antidepressant effects of anesthetic and perioperative drugs: mechanisms, clinical evidence, and translational boundaries

Rapid symptom relief remains an important unmet need in treatment-resistant depression (TRD) and in depressive episodes accompanied by acute suicidal ideation or behavior. This narrative review examines anesthetic and perioperative drugs that have been proposed as rapid-acting antidepressants. N-methyl-D-aspartate (NMDA)-receptor blockade, increased α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) throughput, and brain-derived neurotrophic factor (BDNF)–tropomyosin receptor kinase B (TrkB)–mechanistic target of rapamycin complex 1 (mTORC1) signaling provide a predominantly preclinical account of rapid synaptic plasticity, and randomized trials show improvement in depressive symptoms within hours to days. Ketamine and esketamine have the strongest evidence, with variable response- and remission-rates and limited sustained duration of benefit across studies. Intravenous ketamine can rapidly reduce suicidal ideation, but it does not replace comprehensive suicide-prevention care. Intranasal esketamine reduces depressive symptoms in TRD and in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior; a separate effect on suicidal ideation or suicide prevention has not been demonstrated. Nitrous oxide has encouraging phase 2 evidence, though the primary-outcome point estimate was modest with wide confidence intervals and narrowly missed conventional statistical significance. Evidence for propofol and volatile anesthetics remains limited to small experimental studies. Tramadol is better viewed as a pharmacologic clue than as an antidepressant treatment. Clinical translation requires agent-specific monitoring, defined maintenance and stopping rules, and attention to cardiovascular, respiratory, cognitive, urinary, hepatic, and misuse risks. This is a narrative review without formal meta-analysis; findings should be interpreted considering heterogeneous trial designs and variable sample sizes.

Authors

Institutions

Publication Details

Journal
Frontiers in Psychiatry
Published
2026-11-17
DOI
https://doi.org/10.3389/fpsyt.2026.1995965
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Rapid antidepressant effects of anesthetic and perioperative drugs: mechanisms, clinical evidence, and translational boundaries

Li Hu, Xinyi Wang, Shujun Ren, Jinqi Ma
Frontiers in Psychiatry
Treatment of Major Depression
article

Rapid antidepressant effects of anesthetic and perioperative drugs: mechanisms, clinical evidence, and translational boundaries

Li Hu, Xinyi Wang, Shujun Ren, Jinqi Ma
article en

Abstract

Rapid symptom relief remains an important unmet need in treatment-resistant depression (TRD) and in depressive episodes accompanied by acute suicidal ideation or behavior. This narrative review examines anesthetic and perioperative drugs that have been proposed as rapid-acting antidepressants. N-methyl-D-aspartate (NMDA)-receptor blockade, increased α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) throughput, and brain-derived neurotrophic factor (BDNF)–tropomyosin receptor kinase B (TrkB)–mechanistic target of rapamycin complex 1 (mTORC1) signaling provide a predominantly preclinical account of rapid synaptic plasticity, and randomized trials show improvement in depressive symptoms within hours to days. Ketamine and esketamine have the strongest evidence, with variable response- and remission-rates and limited sustained duration of benefit across studies. Intravenous ketamine can rapidly reduce suicidal ideation, but it does not replace comprehensive suicide-prevention care. Intranasal esketamine reduces depressive symptoms in TRD and in adults with major depressive disorder (MDD) and acute suicidal ideation or behavior; a separate effect on suicidal ideation or suicide prevention has not been demonstrated. Nitrous oxide has encouraging phase 2 evidence, though the primary-outcome point estimate was modest with wide confidence intervals and narrowly missed conventional statistical significance. Evidence for propofol and volatile anesthetics remains limited to small experimental studies. Tramadol is better viewed as a pharmacologic clue than as an antidepressant treatment. Clinical translation requires agent-specific monitoring, defined maintenance and stopping rules, and attention to cardiovascular, respiratory, cognitive, urinary, hepatic, and misuse risks. This is a narrative review without formal meta-analysis; findings should be interpreted considering heterogeneous trial designs and variable sample sizes.

Frontiers in PsychiatryVol. 17
Jiaxing University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province
Good health and well-being
Treatment of Major Depression
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon